PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study

Table 4 Clinical course of patients with PPC harboring PIK3CA mutation

No.	Sex	Age	Stage	Gene mutation status			PD-L1 TPS%	Chemotherapy		OS days	Outcome
No.	Sex	Age	Stage	TP53	ATM	EGFR	PD-L1 TPS%	1st line	ICI	OS days	Outcome
24	F	78	II	Mut	VUSs	WT	10	–	–	1114	Censoring
26	M	70	III	VUSs	WT	WT	0	CBDCA+ETP	–	191	Died
37	M	50	II	Mut	WT	WT	40	CBDCA+nab-PTX	Pembro	665	Died
39	F	81	III	Mut	WT	VUSs	70	Gefitinib	Pembro	535	Died

PPC Pulmonary pleomorphic carcinoma, PIK3CA Gene encoded phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Stage Pathological stage, TP53 Gene encoded tumor protein p53, ATM Ataxia-telangiectasia mutated gene, EGFR Gene encoded epidermal growth factor receptor, PD-L1 Programmed cell death-ligand 1, ICI Immune checkpoint inhibitor, OS Overall survival, VUSs Variants of unknown significance, WT Wild type, Mut Mutation, CBDCA Carboplatin, ETP Etoposide, nab-PTX nanoparticle albumin-bound paclitaxel, Pembro Pembrolizumab